Sanofi, a leading French pharmaceutical company, has recently announced its acquisition of U.S.-based Blueprint Medicines Corporation for up to $9.5 billion. This strategic move aims to bolster Sanofi’s presence in the rare immunology diseases sector, marking the largest deal made by a European healthcare company this year.
Blueprint Medicines Corporation specializes in treatments for systemic mastocytosis, a rare blood disorder. The acquisition will see Sanofi initially paying $129.00 per share in cash, totaling around $9.1 billion. Following the announcement, Blueprint’s shares surged by 27% to $128.74 in premarket trading, while Sanofi’s stock experienced a slight decline of about 1%.
Sanofi’s increased focus on research and development in recent years has led to the abandonment of its long-term profit margin targets. This move is part of the company’s efforts to build on the success of its blockbuster drug Dupixent, used to treat eczema and other conditions. However, Sanofi faced a setback last week when an experimental drug for patients with a lung condition commonly referred to as “smoker’s lung” failed a late-stage trial.
CEO Paul Hudson expressed enthusiasm about the Blueprint acquisition, citing it as a significant step forward in Sanofi’s rare and immunology portfolios. The deal is expected to enhance Sanofi’s pipeline and accelerate its transformation into a leading immunology company globally.
The acquisition of Blueprint Medicines Corporation will bring Ayvakit, the only approved medicine for advanced and indolent systemic mastocytosis, into Sanofi’s portfolio. Additionally, it includes elenestinib, a next-generation medicine for systemic mastocytosis, and BLU-808, a highly selective and potent oral wild-type KIT inhibitor with the potential to treat a range of diseases in immunology.
Analysts at JP Morgan view the deal as strategically and financially sound, noting that Blueprint anticipates Ayvakit to achieve annual sales of approximately $2 billion by fiscal year 2030. They believe the transaction aligns well with Sanofi’s objectives and represents a positive development for investors.
This acquisition is part of a series of deals made by Sanofi, including the recent purchase of Vigil Neuroscience for $470 million and the acquisition of U.S biotech firm Inhibrx for $2.2 billion in January 2024. CEO Paul Hudson emphasized that the Blueprint acquisition complements Sanofi’s earlier acquisitions of early-stage medicines and that the company still has significant capacity for future deals.
In addition to the cash offer, Blueprint shareholders will also receive a non-tradeable contingent value right (CVR) per share, entitling them to potential milestone payments of $2 and $4 per CVR for the achievement of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, amounts to $9.5 billion on a fully diluted basis. The deal is expected to close in the third quarter, pending regulatory and shareholder approvals.
Sanofi has expressed its commitment to investing at least $20 billion in the United States by 2030 to enhance manufacturing and research capabilities, aligning with President Donald Trump’s initiatives to boost local manufacturing in the pharmaceutical industry. The acquisition of Blueprint Medicines Corporation underscores Sanofi’s dedication to advancing its rare and immunology portfolios and solidifying its position as a leading player in the global healthcare landscape.
